Ono Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

November 2024 | 50 pages | ID: O197541E347BEN
BAC Reports

Abstracts

Ono Pharmaceutical Co. Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Ono Pharmaceutical Co. Ltd. and its competitors. This provides our Clients with a clear understanding of Ono Pharmaceutical Co. Ltd. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Ono Pharmaceutical Co. Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Ono Pharmaceutical Co. Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Ono Pharmaceutical Co. Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Ono Pharmaceutical Co. Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Ono Pharmaceutical Co. Ltd. business.

About Ono Pharmaceutical Co. Ltd.

Ono Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development of neuroscience, intracellular signaling, and genomic-based drugs. The company intends to acquire commercialization rights to new drug candidates in early development stages, coordinating with Ono Pharma USA, Inc. and Ono Pharma UK Ltd. in order to expand the development pipeline.

New Drugs in Development

Recalbon Tablets: Recalbon, a drug for the treatment of osteoporosis, is one of the bisphosphonates, preventing bone resorption at low doses and increasing in bone mineral density.

Emend Capsules: Emend is a neurokinin (NK) 1 antagonist. The drug is effective not only for acute phase of chemotherapy-induced nausea and vomiting, but also for delayed phase.

Glactiv Tablets: Glactiv, a dipeptidyl-peptidase (DPP) IV inhibitor, is a new class of drug for type II diabetes and would be useful for control of postprandial hyperglycemia with low risks of hypoglycemia and weight gain in type II diabetes patients.

ONO-2540 / ENA713D (transdermal patch): ONO-2540 or rivastigmine patch is a drug for the treatment of Alzheimer’s disease with an inhibitory action on both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The drug inhibits not only AChE which is known as an enzyme deeply involved in Alzheimer’s disease, but also BuChE which increases as the disease progresses.

Arocyte for Injection: Arocyte is a drug to prevent expansion of cerebral infarction by improving function of astrocyte, a kind of glial cells in the brain.

Cereact Capsules: Cereact is a drug with a novel mechanism of action for the treatment of neurodegenerative diseases. It inhibits the occurrence and progression of neurodegenerative diseases, such as the ‘intractable’ disease amyotrophic lateral sclerosis (ALS), by improving the abnormal activation of astrocytes.

ONO-7643 / RC-1291 (tablet): ONO-7643 is a small-molecule ghrelin mimetic being developed for cancer anorexia / cachexia. The drug has similar pharmacological actions to ghrelin, a circulating peptide hormone with multiple physiological actions, including appetite stimulation, muscle-building (anabolic), and modulation of gastrointestinal functions.

ONO-5334 (tablet): ONO-5334, a cathepsin K inhibitor, is being developed for osteoporosis with a novel mechanism of action.

ONO-4538 / MDX-1106 (injection): ONO-4538, a fully human anti-PD-1 antibody, would be a treatment for cancer and other diseases. PD-1 is one of the receptors expressed on activated lymphocytes, and is involved in the negative regulatory system to suppress the activated lymphocytes.

ONO-8539 (tablet): ONO-8539 is a selective antagonist of EP1, one of subtype receptors of prostaglandin E2, and overactive bladder is the first indication for its clinical development program.

ONO-4641 (tablet): ONO-4641 is a sphingosine-1-phosphate (S1P) receptor agonist, being developed for the treatment of multiple sclerosis. The drug is a low molecular weight substance that keeps lymphocytes in lymph nodes and reduces the lymphocyte count in the blood, as a result inhibiting the infiltration of lymphocytes into lesions.

ONO-7847 / MK-0517 (injection): ONO-7847 is a neurokinin (NK) 1 receptor antagonist, the prodrug of ONO-7436 (Emend Capsule) available in injectable form.

ONO-5920 / YM529 (tablet): ONO-5920 / YM529 is an intermittent oral version of Recalbon Tablets, a drug for the treatment of osteoporosis.

History

Ono Pharmaceutical Co., Ltd. was founded in 1717.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. ONO PHARMACEUTICAL CO. LTD. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. ONO PHARMACEUTICAL CO. LTD. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. ONO PHARMACEUTICAL CO. LTD. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. ONO PHARMACEUTICAL CO. LTD. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. ONO PHARMACEUTICAL CO. LTD. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Ono Pharmaceutical Co. Ltd. Direct Competitors
5.2. Comparison of Ono Pharmaceutical Co. Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Ono Pharmaceutical Co. Ltd. and Direct Competitors Stock Charts
5.4. Ono Pharmaceutical Co. Ltd. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Ono Pharmaceutical Co. Ltd. Industry Position Analysis

6. ONO PHARMACEUTICAL CO. LTD. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. ONO PHARMACEUTICAL CO. LTD. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. ONO PHARMACEUTICAL CO. LTD. ENHANCED SWOT ANALYSIS²

9. JAPAN PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. ONO PHARMACEUTICAL CO. LTD. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. ONO PHARMACEUTICAL CO. LTD. PORTER FIVE FORCES ANALYSIS²

12. ONO PHARMACEUTICAL CO. LTD. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Ono Pharmaceutical Co. Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Ono Pharmaceutical Co. Ltd. 1-year Stock Charts
Ono Pharmaceutical Co. Ltd. 5-year Stock Charts
Ono Pharmaceutical Co. Ltd. vs. Main Indexes 1-year Stock Chart
Ono Pharmaceutical Co. Ltd. vs. Direct Competitors 1-year Stock Charts
Ono Pharmaceutical Co. Ltd. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Ono Pharmaceutical Co. Ltd. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Ono Pharmaceutical Co. Ltd. Key Executives
Ono Pharmaceutical Co. Ltd. Major Shareholders
Ono Pharmaceutical Co. Ltd. History
Ono Pharmaceutical Co. Ltd. Products
Revenues by Segment
Revenues by Region
Ono Pharmaceutical Co. Ltd. Offices and Representations
Ono Pharmaceutical Co. Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Ono Pharmaceutical Co. Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Ono Pharmaceutical Co. Ltd. Capital Market Snapshot
Ono Pharmaceutical Co. Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Ono Pharmaceutical Co. Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Ono Pharmaceutical Co. Ltd. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?